(Q54171136)

25 May 2018

title

Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. (English)

1 reference

25 May 2018

author name string

A Murakami

1

1 reference

25 May 2018

T Mori

2

1 reference

25 May 2018

H Sakai

3

1 reference

25 May 2018

M Murakami

4

1 reference

25 May 2018

T Yanai

5

1 reference

25 May 2018

Y Hoshino

6

1 reference

25 May 2018

K Maruo

7

1 reference

25 May 2018

publication date

17 January 2011

1 reference

25 May 2018

Veterinary and Comparative Oncology

published in

1 reference

25 May 2018

volume

9

1 reference

25 May 2018

page(s)

219-224

1 reference

25 May 2018

issue

3

1 reference

25 May 2018

The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Gastrointestinal stromal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

An immunohistochemical analysis of canine haemangioma and haemangiosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Comparative immunohistochemical characterization of canine seminomas and Sertoli cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Anorectal malignant melanoma: morphologic and immunohistochemical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2010.00253.X

10.1111/J.1476-5829.2010.00253.X

21 January 2018

Identifiers

DOI

1 reference

25 May 2018

PubMed ID

21848624

1 reference

25 May 2018